Insmed Incorporated

NasdaqGS:INSM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 19.92 B

Share Price

USD 101.74

Avg Daily Volume

2,289,787

Change (1 day)

-2.97%

Change (1 year)

47.49%

Change (YTD)

47.36%

Insmed Incorporated Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending March 31, 2025: USD 629.86 M

Insmed Incorporated Research and Development (R&D) Expenses is USD 629.86 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 11.63% change year over year. Research and development (R&D) expenses are the costs associated with the development of new products, technologies, or improvements to existing products.

Insmed Incorporated Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 564.23 M, a 27.94% change year over year.
Insmed Incorporated Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 441.03 M, a 49.14% change year over year.
Insmed Incorporated Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 295.71 M, a 43.30% change year over year.
Insmed Incorporated Research and Development (R&D) Expenses for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 206.36 M, a 50.97% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Research and Development (R&D) Expenses	Revenue	Revenue	Gross Profit

NasdaqGS: INSM

Insmed Incorporated

CEO	Mr. William H. Lewis J.D., M.B.A.
IPO Date	June 1, 2000
Location	United States
Headquarters	700 US Highway 202/206
Employees	1,271
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.